The AstraZeneca trial is allowed to resume

Federal health regulators have decided to allow the resumption of U.S. studies of a leading Covid-19 vaccine candidate from AstraZeneca PLC and the University of Oxford, according to a person familiar with the matter and materials reviewed by The Wall Street Journal.

Here is the WSJ article, no real explanation given by either the company or the FDA.

Comments

Comments for this post are closed